Clinical trial

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Name
Pro00107570
Description
The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
Trial arms
Trial start
2021-11-12
Estimated PCD
2025-03-31
Trial end
2025-03-31
Status
Recruiting
Phase
Early phase I
Treatment
Hyperpolarized 129Xe
Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
Arms:
Healthy Volunteers, Patients with Interstitial Lung Disease
Size
147
Primary endpoint
Thoracic cavity volume measured in liters.
4 years
RBC/barrier signal ratio (unitless).
4 years
Coefficient of repeatability of RBC/barrier signal ratio (unitless).
4 years
Echo time to separate RBC and barrier signals by 90 degrees (ms).
4 years
Population-wide RBC/barrier signal ratio (unitless).
4 years
Eligibility criteria
Inclusion/Exclusion Criteria for Healthy Volunteers Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial: 1. Outpatients of either gender, age greater than or equal to 18 years 2. Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.) 3. Subject has no diagnosed pulmonary conditions 4. Subject has not smoked in the previous 5 years 5. Smoking history, if any, is less than or equal to 5 pack-years 6. No history of using other inhaled products more than 1 time per week for \> 1 year Exclusion Criteria: Subjects presenting with any of the following will not be included in the trial: 1. Subject is less than 18 years old 2. MRI is contraindicated based on responses to MRI screening questionnaire 3. Subject is pregnant or lactating 4. Resting oxygen saturation on room air \<90% 5. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 6. Subject has history of any known ventricular cardiac arrhythmia 7. Subject has history of cardiac arrest within the last year 8. Subject does not fit into Xe vest coil used for MRI 129 9. Subject cannot hold his/her breath for 15 seconds 10. Subject deemed unlikely to be able to comply with instructions during imaging 11. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements Inclusion/Exclusion Criteria for Subjects with Interstitial Lung Disease Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the trial: 1. Outpatients of either gender, age greater than or equal to 18 years 2. Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.) 3. Clinical diagnosis of Interstitial Lung Disease made by a board certified pulmonologist using established criteria. We will not exclude individuals based on ILD type or severity of disease with the exception of the below criteria Exclusion Criteria: Subjects presenting with any of the following will not be included in the trial: 1. Subject is less than 18 years old 2. MRI is contraindicated based on responses to MRI screening questionnaire 3. Subject is pregnant or lactating 4. Resting oxygen saturation \<90% on supplemental oxygen 5. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 6. Subject has history of any known ventricular cardiac arrhythmia. 7. Subject has history of cardiac arrest within the last year 8. Subject does not fit into Xe vest coil used for MRI 129 9. Subject cannot hold his/her breath for 15 seconds 10. Subject deemed unlikely to be able to comply with instructions during imaging 11. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 147, 'type': 'ESTIMATED'}}
Updated at
2024-04-17

1 organization

Organization
Bastiaan Driehuys